Capribose Drug Interactions

Sucrose and food containing often cause abdominal discomfort or even diarrhea during treatment with Acarbose as a result of increased carbohydrate fermentation in the colon.
Acarbose has an antihyperglycemic effect but does not itself induce hypoglycaemia.
If Acarbose is prescribed in addition to drugs containing sulphonylureas or metformin, or in addition to insulin, a fall of the blood glucose values into the hypoglycaemic range may necessitate a suitable decrease in the sulphonylureas, metformin, or insulin dose. In individual cases hypoglycaemic shock may occur.
If acute hypoglycaemia develops it should be borne in mind that sucrose is broken down into fructose and glucose more slowly during treatment with Acarbose; for this reason sucrose is unsuitable for a rapid alleviation of hypoglycaemia and glucose should be used instead.
In individual cases Acarbose may affect digoxin bioavailability, which may require dose adjustment of digoxin.
Because they may possibly influence the action of Acarbose, simultaneous administration of cholestyramine, intestinal adsorbents, and digestive enzyme products should be avoided. No interaction was observed with dimeticone/simeticone.
Drugs that tend to result in hyperglycaemia and may lead to loss of blood glucose control include diuretics (thiazides, furosemide), corticosteroids , phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics and isoniazid. If these drugs are given to patients who are receiving Acarbose, the patients should be closely monitored for loss of blood glucose control.
Due to neomycin induced malabsorption of carbohydrate, concomitant administration of neomycin may lead to an enhanced reduction of post prandial blood glucose and to an increase in the frequency and severity of gastrointestinal adverse reactions. If the symptoms are severe, a temporary dose reduction of Acarbose may be warranted.